Levi & Korsinsky Encourages ESSA Pharma Inc. Shareholders to Join Class Action by Deadline March 25, 2025

ESSA Pharma Inc. Class Action Overview

Levi & Korsinsky, LLP, a law firm renowned for its commitment to shareholder rights, has announced that it is notifying investors of ESSA Pharma Inc. regarding a pending class action lawsuit. The lawsuit, which addresses allegations of securities fraud, is focused on the time frame from December 12, 2023, to October 31, 2024. Investors in ESSA Pharma Inc. (NASDAQ: EPIX) are urged to take note of the lead plaintiff deadline set for March 25, 2025.

Allegations Against ESSA Pharma

The complaint outlines several serious accusations against ESSA Pharma that may have significantly impacted investors. The defendants are accused of making false or misleading statements concerning their drug, masofaniten. Specifically, they allegedly suggested that masofaniten used in combination with enzalutamide offered significant benefits over using enzalutamide alone. However, the lawsuit claims that the M-E Combination Study, which was intended to evaluate this treatment option, did not demonstrate the expected efficacy.

Furthermore, the lawsuit suggests that the defendants overstated masofaniten's prospects regarding clinical trials, regulatory approvals, and commercial viability. This misinformation contributed to the inflated stock value of ESSA Pharma, leading to considerable losses for investors when the truth began to surface.

Next Steps for Investors

For those who believe they might qualify as class members and suffered losses during this period, acting promptly is crucial. Interested parties have until March 25, 2025, to file for lead plaintiff status in court. However, it is important to note that participation in any recovery from the lawsuit does not necessitate serving as the lead plaintiff.

Levi & Korsinsky emphasizes that joining the class action incurs no costs for class members, meaning they may be entitled to compensation without any upfront expenses. This arrangement underscores the firm's commitment to protecting investors’ rights.

Why Choose Levi & Korsinsky?

With over 20 years of experience in securities litigation, Levi & Korsinsky has successfully represented numerous shareholders in high-stakes class actions. They have obtained hundreds of millions in settlements for their clients, establishing themselves as a credible option for investors seeking justice. The firm has a dedicated team of over 70 employees specializing in securities issues and has consistently ranked among the top firms in the field according to ISS Securities Class Action Services.

How to Get Involved

For those who have been affected by the actions of ESSA Pharma, the first step is to reach out to Levi & Korsinsky. Investors can initiate contact by filling out this submission form or by contacting Joseph E. Levi via email or phone. This could be a vital move towards reclaiming lost investments.

Conclusion

As the class action against ESSA Pharma progresses, affected investors have a critical opportunity to join forces and seek reparations. The next few months will be pivotal, with the lead plaintiff deadline rapidly approaching. Investors should stay informed and seek the counsel of experienced legal representatives to navigate this complex situation effectively.